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a  b  s  t  r  a  c  t
In  traditional  Chinese  medicine  (TCM),  multicomponent  and  principally  plant-derived  drugs  are  used
for disease  prevention,  symptom  amelioration  and  treatment  in  a personalized  manner.  Because  of  their
complex  composition  and  consequent  multiple  targets  and  treatment  objectives,  the  application  of  omics
techniques  and  other  integrative  approaches  seems  inherently  appropriate  and  even  necessary  for  the
demonstration  of their  potential  preclinical  and  clinical  safety  and  efﬁcacy.  This  perspectives  article
provides  proposals  for  the application  of  omics  methods  to  the investigation  of  complex  herbal  products
(CHP),1 including  Chinese  herbal  medicines  (CHM),  both  in vitro  and  in  vivo,  for  preclinical  and  clinical
toxicity,  pharmacokinetics,  pharmacodynamics  and  efﬁcacy  tests.  Ultimately,  such  approaches  could  aid
regulatory  scrutiny  and  potential  acceptance,  although  currently  there  is  no  regulatory  requirement  of
omics-based  data  in  any  submitted  dossier  to any  regulatory  agency,  including  for conventional  drugs  and
CHP.  However,  it has  been  acknowledged  that  such  studies  are  being  increasingly  performed,  and  almost
surely  will  eventually  be  included  into  regulatory  submission  dossiers,  possibly  initially  as supplementary
materials.  Speciﬁcally  for CHM  and  CHP,  omics  can  play  a  role  both  in  determining  product  composition
and  its  variability  and  in  monitoring  biological  effects  in carefully  selected  platforms.  Predicting  the  future
is difﬁcult,  but it seems  possible  that  regulatory  acceptance  of  omics  techniques  and  a systems  biology
approach  for  the  study  of  TCM,  CHM  and  CHP  will  not  be long  delayed.  It  is  expected  that  current  studies
and  plans  employing  omics  techniques  and  other  integrative  approaches  will  prove  to  be  positive  and
informative.. IntroductionIn the USA, the Food and Drug Administration (FDA) has
tated that: “Omics technologies are high throughput2 technologies
∗ Corresponding author at: University of Oulu, Department of Pharmacology and
oxicology, POB 5000, Aapistie 5 B, 90014 Oulu, Finland. Tel.: +358 40 5075196.
E-mail address: olavi.pelkonen@oulu.ﬁ (O. Pelkonen).
1 Complex herbal products are used in many other forms of Asian medicines
han Chinese medicines, such as traditional Indian medicine (Ayurveda), Japanese
edicine (Kampo), Korean medicine, Tibetan medicine etc., although the conceptual
ackground for use may differ.
2 Authors’ note: Here, “high throughput” refers to both information-rich, provid-
ng high-throughput information on a whole proﬁle of DNA, RNA, protein and/or
etabolites in any individual samples, and also high-throughput in terms of sample
ize, enabling to handle many samples in short time.
378-8741     © 2012 Elsevier Ireland Ltd     . 
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Open access under CC BY-NC-ND license.© 2012 Elsevier Ireland Ltd. 
used to analyse various kinds of macromolecules,3 simultane-
ously; for example, transcriptomics measures many transcripts,
proteomics measures many proteins and metabolomics measures
many metabolites. High throughput technologies are large scale
methods to purify, identify, and characterize DNA, RNA, proteins
and other molecules. These methods are usually automated, allow-
Open access under CC BY-NC-ND license.ing rapid analysis of very large numbers of samples.4” (FDA-TRACK
Research Glossary Page; Last Updated: 05/04/2011). In the EU, the
European Medicines Agency (EMA) has not established any formal
3 Authors’ note: Small molecules, too.
4 Authors’ note: This is true, but the real strength of omics technolo-
gies is to address whole proﬁles of DNA (genomics), RNA (transcriptomics),
proteins (proteomics) and metabolites (metabolomics) through comprehensive
bioinformatics-based analysis, regardless of sample number.
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Table  1
Representative examples of pharmacogenomic biomarkers used in labelling of the medicinal product in the individual summary of product characteristics (source: www.ema
and  appropriate EPAR/SPC for each preparation).
Drug Biomarker Scope/target Remarks
Abacavir HLA*B5701 Safety Hypersensitivity reactions
Carbamazepine HLA-B*1502
HLA-A*3101 Safety Remarkable ethnicity associated
adverse drug reactions
Clopidogrel CYP2C10 Efﬁcacy PM poor efﬁcacy
Dasatinib PH + chromosome Efﬁcacy Patient selection under indication
Erlotinib EGRF Efﬁcacy Patient selection under indication
Fulvestrand ER Efﬁcacy Patient selection under indication
Geﬁtinib EGFR Efﬁcacy Patient selection under indication and pharmacodynamics
Lapatinib HER2 Efﬁcacy Patient selection under indication
Maraviroc CCR5 co-receptor Efﬁcacy Patient selection under indication
Nelﬁnavir CYP2C19 Safety PM toxicity and interaction
Nilotinib PH chromosome Efﬁcacy Patient selection under indications
Phenytoin HLA-B*1502 Safety Increased risk for Steven-Johnson syndrome according to ethnicity
Tamoxifen CYP2D6 Efﬁcacy/drug-drug interactions PM less efﬁcacy, due to DDI an alternative therapeutic approach proposed
Patient selection
A r metabolizer.
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Box 1: Crucial steps to be taken into consideration
when creating biomarkers for regulatory purposes
(based on the biomarker qualification exercise as
described in Dieterle et al., 2010)
(1) Identiﬁcation of biomarkers from non-clinical or clinical set-
ting (all omics techniques are basically capable of creating
tentative lists of potential biomarkers)
(2) Prioritization of identiﬁed biomarkers (on the basis of
potential biomarker sets created in point 1)
(3) Characterization of biomarkers
(4) Validation of biomarkers
(5) Preliminary exercise with prioritized biomarkers
– Linking to non-clinical or clinical endpoint or biological
process
(6) Qualiﬁcation/veriﬁcation of biomarkers
– Reproducibility and transferability of assays between lab-
oratories and processes
– Suitability of an assay: accuracy, precision, limit of quan-
tiﬁcation (LoQ), stability of an analyte, etc.
(7) Acceptance of biomarkers for regulatory useTrastuzumab HER2 Efﬁcacy 
bbreviations:  DDI; drug-drug interactions; PH philadelphia chromosome; PM;  poo
hrasing for omics. However, for pharmacogenetics, pharmacoge-
omics and related deﬁnitions, the EMA  follows nomenclature as
escribed in the International Conference on Harmonization (ICH)
5 document (EMEA/CHMP/ICH/437986/2006).
Due to improvements in analytical technologies and the avail-
bility of greater computational power, new approaches have been
eveloped for generating data sets to provide increased mecha-
istic understanding within molecular biology, an approach often
alled systems biology. This then provides integration of data over
ifferent levels of molecular biology, as opposed to a reductionist
pproach that aims to study in great detail one gene, enzyme or
etabolic process. Systems biology as a term began to gain accep-
ance with the completion of a number of genomes and a huge
xpansion in availability of multivariate data from various omics
echnologies, all being accompanied by advances in computation,
tatistics and bioinformatics. The main levels of organization con-
idered in systems biology comprise genomics, transcriptomics,
roteomics and metabonomics (also called metabolomics), i.e.,
ultivariate analyses at the genome, gene transcription, protein
nd metabolite levels, respectively. Metabonomics comprises the
omprehensive and simultaneous proﬁling of multiple metabolites
n a biological system, as well as their temporal changes caused by,
or example, genetic, environmental and pharmaceutically induced
ffects. Many other omics terms have been invented, but only a few
f these are in wide use and have gained general acceptance (e.g.,
ipidomics and metallomics).
For example, the EMA  and FDA do accept pharmacogenetic
nformation for several pharmaceuticals mainly used in cancer
herapy (see Table 1 and its examples drawn from Agencies’
ocuments). They also sometimes request such data if preclinical
tudies suggest clinically signiﬁcant consequences, for example
hen polymorphic enzymes such as CYP2D6 are of major impor-
ance in the clearance of a substance. All major drug regulatory
gencies as well as academia and industry are involved in initia-
ives, e.g., safety testing consortia, to assess the usefulness of omics
echniques in toxicity testing and to discover novel biomarkers
o be used in translational and clinical studies (Leighton, 2005;
eighton et al., 2006; Lindon et al., 2005; Collins, 2011; Hamburg,
011). Although these initiatives have provided promising results,
hey are of more signiﬁcance in aiding preclinical and clinical
rug development only rather than supplying crucial pieces of
nformation to regulatory bodies. It may  be appropriate to note
hat omics approaches, by their nature, have to date been more
ypothesis-producing exercises than providing ﬁrm mechanistic
nformation. The same applies also to other systems biology
pproaches, however promising they seem to be (Box 1 ).This perspectives article is structured in the following way:
Firstly, we  summarise to what extent omics techniques are used
as part of the regulatory process for conventional pharmaceuticals,
i.e., the current status in various regulatory agencies. Secondly, we
then discuss ensuing implications. Principally, this is the question
as to whether omics techniques could be applied to obtain reli-
able results for complex mixtures regarding pharmacological and
toxicological effects, so as to be able to inform regulatory decisions.
Some of the more obvious and detailed questions, such as
whether publically available omics data bases should be estab-
lished (e.g., for hepatotoxicity and nephrotoxicity) and how to use
omics technologies to specify reference materials and to assess the
validity of variables in a CHP will be more thoroughly discussed in
other articles of this special issue.
It appears that, given the complex and variable composition of
CHP and their multiple mechanisms of biological effects, it would
be desirable to use as comprehensive as possible information gen-
erating approaches to allow for serendipitous discoveries. Thus,
efforts should be directed to the application of omics methods
in vitro and in vivo and for toxicity testing pharmacokinetic and
pharmacodynamic studies and for efﬁcacy evaluation in both
clinical and preclinical phases. This is likely to gain acceptance
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nitially for conventional drugs and then be followed by CHP,
or the purposes of regulatory scrutiny and potential acceptance.
hether this is possible with current technologies, we can only
peculate. Additionally, one can ask in what kind of in vitro/in vivo
latforms such evaluations should be carried out to get maxi-
um  information for the regulatory decision making? Obviously
iscussions on the overall testing strategies should be opened.
evertheless, it seems clear that global and integrative approaches
ill become principal tools in current and future endeavours to
ntegrate Western and Chinese medicines.
. The use of omics-based approaches in current drug
iscovery and development
The pharmaceutical industry, working often together with the
cademic community, has been searching for ways to utilize omics
echniques to improve the drug discovery and development pro-
ess by reducing timescales and compound attrition. In the ﬁeld
f new drug target selection and in general early drug discovery,
he focus has been on pharmacogenomics, but more recently the
ater stages have also been increasingly covered, for example, tran-
criptomic proﬁling of patients in clinical trials (Bilello, 2005; Hu
t al., 2005). One of the ﬁrst examples was the use of genomics
tudies in deﬁning the diagnostic test for the therapeutic use of
erceptin (trastuzumab) (Ross et al., 2009). This opened a new ﬁeld
n drug therapy, i.e.,  theranostics, which seems to have become
ommonplace especially in oncology and provides an example for
ersonalized therapy in general (see Table 1). Personalized ther-
py, as in the above example, or more generally stratiﬁed medicine
argeted at sub-groups of patients will clearly rely heavily on omics
pproaches to be effective since this represents probably the only
ay to identify the particular phenotype that will respond to a given
reatment (Clayton et al., 2006, 2009; Siest et al., 2009; Nicholson
t al., 2011).
However, in terms of regulatory support, thus far out of the
arious omics techniques, only pharmacogenomic data have been
pplied to pharmaceuticals (Table 1) while the real usefulness of
echniques and platforms for metabonomics and proteomics are
till pending. Obviously initiatives to introduce epigenome-wide
ssociation studies to demonstrate “static” or “dynamic” changes
n genomes in regulatory purposes are also to be expected.
. Regulatory considerations: current situation
So far, there is no requirement to perform and include omics-
ased studies in a dossier to a regulatory agency, either FDA or EMA.
lso there is no general agreement among regulators on how to use
hese data, should such data set be included in a dossier. The main
nterest among the regulators has been the use of pharmacoge-
omic data mainly for efﬁcacy prediction and personalization and
ess as part of safety evaluation, although examples such as nephro-
oxicity biomarker qualiﬁcation exercises (Dieterle et al., 2010) and
ersonalized medicine targeting approaches (Sim and Ingelman-
undberg, 2011) do exist. However, it has been acknowledged that
uch studies are being increasingly performed and those studies
ould be included into a FDA dossier as supplementary materials
MacGregor, 2003). As yet, all major drug regulatory agencies are
till in the process of assessing the usefulness of omics-based stud-
es in the assessment of new pharmaceuticals. The industry has
aunched initiatives, e.g., safety testing consortia, and together with
he European Commission, it supports an Innovative Medicines Ini-
iative (IMI) approach, to assess the usefulness of omics techniques
n toxicity testing and to discover novel biomarkers to be used
n translational and human clinical studies, information of which
ould ultimately be included in a dossier. In the USA, the FDA is armacology 140 (2012) 587– 593 589
partner in multipartner projects such as Tox21c, which rely heavily
on the use of omics techniques and systems biology.
Obviously the main drawback in the regulatory use of omics
data is that the whole omics ﬁeld and associated techniques are
rapidly developing and, therefore, any standards and regulatory
“minimum” requirements set using current approaches, would be
drastically and severely outdated very soon. Additionally, it has
proved impossible at present to deﬁne what would be the reference
data set against which new data will read, and how data sharing
among different bodies would be arranged without violating con-
ﬁdentiality. However more optimistically, whilst transcriptomics
technologies are changing rapidly and associated data formats
might be unstable, this is less true for proteomics where the largely
mass spectrometry (MS) based platforms are more stable and data
will still be capable of being read and interpreted for many years
even if the hardware for data measurement alters. At the metabolic
level the situation is more stable with the two  main technologies,
nuclear magnetic resonance (NMR) spectroscopy and MS,  being
well understood and stable, and this is particularly true for NMR.
At all omics levels considerable effort has been put into methods
and data standardization and various reports have been produced
for transcriptomics (Brazma et al., 2001), proteomics (Taylor et al.,
2007) and metabonomics (Sansone et al., 2007), respectively.
3.1. The EU
If signiﬁcant ﬁndings have been made, pharmacogenetics/
genomics information can be included into a dossier submitted to
EMA  on a voluntary basis. The inclusion of such ﬁndings seems to
be related to the severity of disease or adverse reaction. Pharmaco-
genetic/genomic information has already been applied to several
pharmaceuticals in the cancer therapy area, e.g., tamoxifen, aba-
cavir, Herceptin (Table 1). Currently there are no initiatives to apply
other omics techniques unless they belong to projects to search
for biomarkers. An interesting current activity is concerned with
a search of suitable biomarkers to detect nephrotoxicity. Several
candidate biomarkers have been considered for validation studies.
Schematic steps for how to develop a biomarker(s) for regulatory
purposes are summarized in Table 2. In the past, toxicologists in
EMA Safety Working Party and European Federation of Pharma-
ceutical Industries and Associations (EFPIA) had an initiative to
establish a discussion forum for omics in toxicology/safety testing,
but it no longer seems to be active. This discussion forum should
be reopened.
3.2. USA, Canada and Japan
Similar to the EU, the inclusion of omics information in the
regulatory dossier is on a voluntary basis only. As EU, also these
countries participate in the International Conference on Harmo-
nization processes, which are going relatively slowly ahead.
3.3. China
No information about the inclusion of omics information in the
regulatory dossier was  publicly available. However, a general reg-
ulatory situation concerning TCM in China is completely different
from that in other major countries (Jiang et al., 2011). For exam-
ple, in the National Essential Drug List there are 102 TCM products
out of 307 drugs and TCM products are recommended to treat
patients with chronic diseases. In the National Health Insurance
Drug List there are 683 TCM products, also called proprietary Chi-
nese medicines. The value of TCM products industry represents
about 30% of the total value of the pharmaceutical industry in China.
Furthermore, there are numerous functional food products con-
taining mostly Chinese Materia Medica ingredients. It would be of
590 O. Pelkonen et al. / Journal of Ethnopharmacology 140 (2012) 587– 593
Table  2
Omics studies of CHP: an ADMET (absorption, distribution, metabolism, excretion, toxicity) scheme.
Study speciﬁcs Purpose Methods Outcome
Herbal substance/preparation Identiﬁcation and quantitation of
major and minor components
LC–(TOF)MS/MS “Xenometabolome” of the
preparation (composition of the
preparation; principal ‘active’
components)
Subcellular organelles (microsomes), primary and
permanent cells in culture
Metabolism, identiﬁcation and
quantitation of metabolites
LC–(TOF)MS/MS In vitro “xenometabolome” after
metabolism rate of metabolism
(clearance), metabolic proﬁle
major and minor constituents of the herbal substance Identiﬁcation of metabolizing
enzymes
Recombinant enzymes,
enzyme-selective inhibitors,
antibodies
Enzymes catalyzing different
pathways (especially of ‘active’
components)
Intestinal cells (Caco-2 etc.), hepatocytes in culture Permeation, transporters,
metabolism
LC–MS, inhibitors of transporters Rate of permeation, contribution of
transporters
Cryopreserved primary hepatocytes, HepaRG cells Hepatotoxicity Cytotoxicity (MTT, LDH,etc.)
All omics techniques for
identifying biomarkers (e.g. Nrf-2
and other biomarkers)
Quantitative in vitro potential of
hepatotoxicity
Other  cells (renal, neural, immune etc.) Other toxicities All omics techniques for
identifying biomarkers
assessment of potential toxicity
Volunteers, patients: Administration of preparation or
components
In vivo kinetics of herbal and/or
components
LC–MS/MS In vivo “xenometabolome”.
Bioavailability
Biomarkers In vivo biomarkers for detecting
product-associated changes
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WC–MS, liquid chromatography–mass spectrometry; LC–(TOF)MS/MS, liquid chroma
ssay); LDH, lactate dehydrogenase (cytotoxicity assay).
nterest to know of how much Chinese drug industry has carried
ut omics research with their products in experimental settings.
.4. Possible changes in the regulatory landscape by 2015 and
ater
The regulation of pharmaceuticals is currently in a ﬂuid change,
nd this could mean both opportunities for and threats to CHP. In
oad Map  to 2015: The European Medicines Agency’s Contribution
o Science, Medicines and Health,5 an ofﬁcial publication adopted
y the EMA Management Board on 16th December 2010, there
re a number of aspects that relate to this article. The executive
ummary lists “the speciﬁc considerations relating to herbal
edicines” and this theme is developed brieﬂy later, although
otally from the European tradition point of view. In the “Strategic
rea 1: Addressing Public Health Needs”, one of the objectives is
o “facilitate new approaches to medicine development” with an
mpact/result indicator measuring how the “existing model for
edicine regulation is adapted to enable integration of new and
merging science”. It seems obvious that authors of the document
ad omics technologies and systems biology approaches in mind,
mong others. Later on the document states that “the concept
f personalized medicine is steadily evolving from a theoretical
oncept into an integral part of modern medicine. And later . . .
rimarily in the oncology ﬁeld”. It continues that “some centrally
uthorized products already have personalised (pharmacoge-
omics) indications in the approved product information”. “. . . to
ddress these challenges (the agency) plans . . . to advise in the
eld of human medicines . . . on the necessary adaption of the reg-
latory framework to the new technologies”. Elsewhere there is a
emark “there is thus a need for debate on how best to support and
ranslate the new science into regulatory requirements”. Later on
n the document, in a section on beneﬁt/risk assessment and com-
unication, there is a note on “patient empowerment and patient
articipation . . . should lead to patients’ utilities being taken into
ccount . . . as well as a more “‘staggered’ approval” regarding the
arketing authorization. The short excerpts quoted above may
5 http://www.ema.europa.eu/docs/en GB/document library/Report/2011/01/
C500101373.pdf.hy–(time-of-ﬂight) tandem mass spectrometry; MTT, tetrazolium salt (cytotoxicity
mean that emerging approaches and techniques could lead to a
more ﬂexible drug approval and regulation, probably ultimately
even to a paradigm shift. Novel techniques enabling personalized
medicine fused with value judgments and quality of life consid-
erations of patients could mean a considerable overhaul of the
medicinal armamentarium as we  know it today. It may  also mean
a re-assessment of other therapeutic traditions with the help of
advancing scientiﬁc approaches and tools. Whatever the outcome,
it is clear that the regulators are considering how omics approaches
could be incorporated into their decision-making processes.
Also other regulatory agencies and closely associated insti-
tutions have similar plans. For example, the FDA stresses the
use of new tools, including functional genomics, proteomics,
metabonomics, high-throughput screening and systems biology,
in advancing regulatory science (Hamburg, 2011). One of the most
important tools in this work is the founding of a new centre at the
National Institutes of Health, the National Center for Advancing
Translational Sciences (NCATS), which endeavours to change the
current thinking in the main areas of translational research, includ-
ing therapeutic target validation, chemistry, virtual drug design,
preclinical toxicology, biomarkers, efﬁcacy testing, phase zero clini-
cal trials, rescuing and repurposing and clinical trial design (Collins,
2011). In many ways, this comprehensive undertaking resembles
the parallel attempt in the EU with the IMI  process.
4. Regulatory considerations: possibilities of omics for
CHM and CHP
4.1. Nature of CHP, including CHM
CHP are composed of plant extracts, often from several plant
species. They contain a large number of chemical constituents,
some of them in abundant amounts (relative to the whole prepara-
tions), but most in relatively minute amounts. Although sometimes
it is possible to pinpoint an individual component (or a group of
components) to be responsible for the characteristic pharmacolog-
ical action, a more general notion is that it is the whole preparation
that is behind the therapeutic action. It should also be borne in
mind that there can be considerable batch-to-batch variability in
composition since this will depend on plant growing locations,
harvesting techniques, storage and decoction preparation. Such
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ulti-component therapeutics, including herbal medicines, are
eﬁned as ‘a concerted pharmacological intervention of multi-
le compounds interacting with multiple targets and possessing
utually interdependent activities that are required for an opti-
al  effect’ (Chan, 1995). With complex medicines, the interactions
etween components of the medicine and potential molecular
argets are more complex than those associated with a single
hemical entity. In particular the authors stressed that the active
rinciple in CHM is actually the whole complex medicinal prepa-
ation (via a multitude of direct and indirect interactions) and
hat the efﬁcacy cannot be realized by puriﬁed component(s).
onsequently, the reductionistic approach, which has been, and
till is, behind the development and use of conventional single-
omponent medicines, is not appropriate for multi-component
edicines (Xue and Roy, 2003). Instead, more global, systems biol-
gy approaches should be applied (Wang et al., 2009). As an example
here is a study in which kava-kava was administered to rats
nd pan-genomic gene expression proﬁling showed hundreds of
hanges in gene expression reading (Guo et al., 2009, 2010). This
xample demonstrates clearly that herbals have direct effects on
ene expression and, therefore, omics technologies could be used
s tools for proof-of-concept and non-clinical efﬁcacy/safety stud-
es to unravel molecular mechanisms of the pharmacological effects
f CHM.
.2. How omics could help regulation of CHP – a possible scenario
Because herbals are complex mixtures of largely “unknown
omponents”, it is reasonable to choose a study strategy that tries to
ssess the whole medicine (with all multiple components) in the
ontext of multiple (global) biological targets at a time rather (a
global or holistic’ approach) than try to target a “speciﬁc” response
o a speciﬁc component of the mixture. Based on the examples
rom non-clinical omics studies measuring gene expression and
etabolic changes (see below) and demonstrating such effects by a
erbal preparation, this kind of holistic approach could – provided
he data evaluation is carried out carefully – help in identiﬁcation
f potential beneﬁts and hazards. However, once again we  can ask
n what kind of test systems such testing should be carried out to
over needs for the regulatory decision making?
Metabolomics, i.e.,  simultaneous analysis of a large num-
er of (endogenous and exogenous) organic chemical substances
‘metabolites’), has been suggested as a way to link TCM and “classi-
al” molecular pharmacology (Wang et al., 2005; Qiu, 2007). During
ecent years, several articles using metabolomics as a new tool to
tudy TCM in experimental animals have been published (Chen
t al., 2007, 2008b; Wang et al., 2007, 2008; Zhao et al., 2008; Sun
t al., 2009). It is obvious that these studies have demonstrated
he feasibility using metabolomics in CHP studies. In addition to
he use in basic research, applications potentially informing regu-
atory assessment and decision making are increasingly emerging
nd below we provide some recent examples together with some
erspectives to the future.
.3. Analytical and pharmaceutical aspects of omics in TCM
tudies
Metabolomic approaches have been increasingly used in the
haracterization and quality control of botanicals and herbal
edicinal products (Wang et al., 2004; Holmes et al., 2006;
han et al., 2007; Li et al., 2007; Ma  et al., 2008; Xie et al.,
008, 2009). In the past one of the most common approaches
as been the determination of an index component and using
his for standardization. Obviously this approach has severe
imitations for the simple reason that one component may  or
ay  not represent the whole substance or preparation. Instead, armacology 140 (2012) 587– 593 591
more comprehensive technique, preferably metabolomics, would
provide a global ﬁngerprint-like signature for the preparation,
which can be used for quality control. A recent case study on the
comprehensive quality control of Huangqin Tang and a four-herb
Chinese medicine PHY906 outlines both chemical and biological
ﬁngerprinting as highly reliable tools for such a task (Tilton et al.,
2010). An interesting experimental follow-up was  a recent study
on the use of PHY906 to reduce irinotecan-induced gastrointestinal
toxicity in mice (Lam et al., 2010).
In the literature, there are only a few published studies on the
use of metabolomics to elucidate the pharmacokinetic details of
botanicals or CHP (Fardet et al., 2008; van Velzen et al., 2009). How-
ever, an integrated approach involving metabolomics, kinetics and
dynamics, especially with regard to toxicity has been applied to
ordinary drugs and toxicants (Chen et al., 2008a; Cho et al., 2009; Liu
et al., 2009a,b; Sun et al., 2009a,b) and this approach may  serve as
an example for CHP. The use of metabolomics in various processes
of pharmacokinetics is especially important for the transforma-
tions and disposition of major and minor components of a herbal
preparation while they are absorbed (bioavailability, biotransfor-
mation in the gut), metabolized (especially liver), distributed and
excreted.
Many TCM products, e.g., CHM, could act via perturbation of the
gut microﬂora and this then brings the need for characterization
of these colonies (Holmes et al., 2011) and the requirement for
metagenomics as well as all of the other omics.
In the preclinical phase of pharmacodynamics and safety
pharmacology, all omics approaches hold promise in uncovering
response proﬁles and dose/concentration–response of metabolom-
ically deﬁned herbal medicines and associating speciﬁc proﬁles and
individual components with speciﬁc pharmacodynamic responses.
In this way, the omics approaches should help identify and develop
potential biomarkers for clinical studies.
It is clear that human clinical trials and other types of clini-
cal studies supply the deﬁnite proof for therapeutic response and
beneﬁt–risk ratio. However, it is known that the gold standard
of clinical trials, randomized, double-blinded, placebo-controlled
human studies (RCT), are good for revealing efﬁcacy in a care-
fully selected patient group, but bad for accounting for variability
in real life and non-selected patient populations. RCT is also an
extremely expensive tool to study preventive effects of medicines,
because huge numbers of humans have to be recruited. The tradi-
tional use of CHP primarily incorporates a personalized approach
and emphasis on prevention rather than a single disease targeted
therapy with conventional mono-component drugs. Consequently,
because of the emphasis on individualization and prevention,
the use of omics approaches in connection with human studies
is even more promising than it is for conventional medicines.
Multiple medicine- and patient- and symptom/disease-associated
biomarkers could be one of the beneﬁcial tools for future clini-
cal studies on CHM and CHP. One of the beneﬁts of metabolomics
in particular is that the data are usually acquired from bioﬂu-
ids collected non-invasively. This allows a metabolic trajectory
to be collected for each subject/patient and thereby, after ther-
apeutic intervention, each patient can act as their own control.
Combining groups of patients and making comparisons of their
metabolic trajectories then adds additional information (Kinross
et al., 2011).
One unique possibility is the use of multi-variate statistical
approaches to relate the multivariate compositional data of the
CHP to the multivariate metabolic (or other omics) readout from
the patient in order to build predictive mathematical models of
the CHP effects as has been done for transcriptomic–metabolomic
cross-correlation (Bylesjö et al., 2007).
Evaluations of clinical efﬁcacy and utility of CHM and CHP
conducted by, for example, Cochrane reviews have provided
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ather mixed conclusions. However, clinical studies with CHM
nd CHP have been increasingly performed in the past decade and
ecommendations for improvements have been suggested (Jiang
t al., 2010).
.4. Omics for absorption, distribution, metabolism, excretion and
oxicity (ADMET) study
As stated previously, the efﬁcacy of CHP in the prevention and
reatment of complex diseases is thought to be due to a number
f active components exerting their effects on multiple targets,
ossibly also acting synergistically. However, there is insufﬁcient
nowledge to assess how the pharmacokinetic behaviour and efﬁ-
acy and toxicity are determined in complex mixtures and whether
here are so called matrix effects and interactions between compo-
ents affecting the fate and effects of the total mixture. In Table 2
ne possible scheme of studies to be included within the regu-
atory dossier of CHP is presented. Firstly, the metabolism and
etabolic interactions of complex mixtures and their main com-
onents are studied in in vitro systems, principally human-derived
issue preparations such as hepatocytes. Secondly, associations
etween the metabolic and kinetic behaviour and selected in vitro
oxicity outcomes in general (e.g., cytotoxicity in hepatocytes) or
n speciﬁc markers (e.g., reactive intermediates, Nrf2 expression)
re elucidated. Thirdly, the most relevant ﬁndings and predic-
ions to in vivo investigations in human volunteers/patients and
n selected cases to experimental animals are carried out. The goal
s to develop a scheme on how to elucidate the ADMET proper-
ies of complex mixtures in in vitro systems so that the results
an be reliably extrapolated and extended to in vivo. Needless to
ay, this scheme is still highly conjectural and based on the current
iews of conventional drugs, but it could be a feasible starting point
or investigations directed towards an evidence-based regulatory
ossier.
. Discussion and conclusions
Bridging TCM and Western medicine is certainly a multifaceted
hallenge, both conceptually and scientiﬁcally. However, recently
here have been attempts to search for common grounds and build
cientiﬁcally viable leads for the integration (Kang, 2008; van der
reef et al., 2010; Lu et al., 2011). It is expected that combining
everal ongoing scientiﬁc and clinical developments in the study of
HM would offer a common ground for integration. Such develop-
ents include the systems biological investigations of mechanisms
f actions of CHM, ensuing identiﬁcation of potential biomarkers
o be associated with both Western disease concepts and TCM
attern classiﬁcations, and quality of life instruments to monitor
atient-reported outcomes, which are in the heart of personalized
edicine. Because the above tools are applicable in both medical
raditions (admittedly, they are developed in Western science) and
heir results could be, at least in principle, made interpretable in
oth traditions, there is every reason to expect that the outcome is
n integrated medical system using the best approaches from both
raditions, but this time based on scientiﬁc evidence. If these expec-
ations will be realized in the future, it means almost automatically,
hat systems biological tools will be in the heart of regulatory sci-
nces and the regulatory process of respective agencies all over the
orld.
It is also possible, and there are certain signs of the change, that
estern concepts of diseases and their causations and treatments
ill become closer to TCM. A recent example is, albeit at a very rudi-
entary stage, the emerging concept of network pharmacology, in
hich low doses of multiple drugs are used to treat often intractable
iseases (see Ainsworth, 2011). Network pharmacology representsrmacology 140 (2012) 587– 593
an attempt to understand complex diseases and their treatments as
networks, for which the most efﬁcient way of treatment is multi-
targeted. Another interesting example is a view of the human body
as a superorganism consisting of cells of both human and symbi-
otic microorganisms (Zhang et al., 2011). This approach emphasizes
the functions of gut microbiota in human health, for which omics
technologies and systems biology tools can be used to study the
dynamic interactions of this superorganism in health and disease.
Application of functional metagenomics developed during the past
two decades would provide a new platform to understand and
modernize TCM (Zhao and Shen, 2010; Zhang et al., 2011).
One question is whether the application of omics technology
is too expensive for routine regulatory use. Undoubtedly the cost
of genomic and transcriptomic proﬁling is reducing dramatically
with a consequent increase in speed. This makes the use of tech-
nologies much more accessible. For metabolomics at least the cost
per analyte is low despite the high cost of the equipment. For
metabolic proﬁling and proteomics in particular, one can envisage
two phases, a discovery phase using high capital cost methods and
highly trained personnel to discover biomarkers, then when these
are known, cheaper or even disposable methods could be used for
the actual tests.
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